Estimation of COVID-19 vaccine effectiveness against hospitalisation in individuals aged ≥ 65 years using electronic health registries; a pilot study in four EU/EEA countries, October 2021 to March 2022

Author:

Sentís Alexis1ORCID,Kislaya Irina2,Nicolay Nathalie3,Meijerink Hinta4,Starrfelt Jostein4,Martínez-Baz Iván56,Castilla Jesús56,Nielsen Katrine Finderup7,Hansen Christian Holm7,Emborg Hanne-Dorthe7,Nardone Anthony1,Derrough Tarik3,Valenciano Marta1,Nunes Baltazar2,Monge Susana89,

Affiliation:

1. Epidemiology Department, Epiconcept, Paris, France

2. Instituto Nacional de Saúde Doutor Ricardo Jorge (INSA), Lisbon, Portugal

3. Vaccine preventable diseases and Immunisation, European Centre for Disease Prevention and Control (ECDC), Solna, Sweden

4. Norwegian Institute of Public Health (NIPH), Oslo, Norway

5. CIBER on Epidemiology and Public Health (CIBERESP), Madrid, Spain

6. Instituto de Salud Pública de Navarra - IdiSNA, Pamplona, Spain

7. Statens Serum Institut (SSI), Copenhagen, Denmark

8. CIBER on Infectious Diseases (CIBERINFEC), Madrid, Spain

9. Instituto de Salud Carlos III (ISCIII), Madrid, Spain

Abstract

By employing a common protocol and data from electronic health registries in Denmark, Navarre (Spain), Norway and Portugal, we estimated vaccine effectiveness (VE) against hospitalisation due to COVID-19 in individuals aged ≥ 65 years old, without previous documented infection, between October 2021 and March 2022. VE was higher in 65–79-year-olds compared with ≥ 80-year-olds and in those who received a booster compared with those who were primary vaccinated. VE remained high (ca 80%) between ≥ 12 and < 24 weeks after the first booster administration, and after Omicron became dominant.

Publisher

European Centre for Disease Control and Prevention (ECDC)

Subject

Virology,Public Health, Environmental and Occupational Health,Epidemiology

Reference15 articles.

1. European Centre for Disease Prevention and Control (ECDC). Overview of the implementation of COVID-19 vaccination strategies and deployment plans in the EU/EEA. Stockholm: ECDC; 21 Apr 2022. [Accessed 13 Jun 2022]. Available from: https://www.ecdc.europa.eu/en/publications-data/overview-implementation-covid-19-vaccination-strategies-and-deployment-plans

2. European Centre for Disease Prevention and Control (ECDC). Weekly epidemiological update: Omicron variant of concern (VOC) – week 2 (data as of 20 January 2022) EU/EEA. Stockholm: ECDC; 21 Jan 2022. [Accessed 16 Jun 2022]. Available from: https://www.ecdc.europa.eu/en/news-events/weekly-epidemiological-update-omicron-variant-concern-voc-week-2-data-20-january-2022

3. Chapter 10: Analysing data and undertaking meta-analyses. Cochrane Training. [Accessed 13 Jun 2022]. Available from: https://training.cochrane.org/handbook/archive/v6.2/chapter-10#section-10-3

4. European Centre for Disease Prevention and Control (ECDC). Engagement of ECDC in projects funded through the Horizon 2020 call for Pan-European COVID-19 cohorts. Stockholm: ECDC

5. 9 Jun 2020. Available from: https://www.ecdc.europa.eu/en/news-events/engagement-ECDC-projects-funded-through-call-for-Pan-European-COVID-19-cohorts

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3